Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26522315 | 0.89 | CTSA (0.34) | CTSAACHEALDH1A1KDM4E | |
| SCHEMBL24760362 | 0.86 | CTSA (0.32) | CTSAACHE | |
| SCHEMBL24509027 | 0.79 | CTSA (0.37) | CTSAACHEKDM4E | |
| SCHEMBL24508556 | 0.77 | KDM4E (0.41) | CTSAACHEALDH1A1KDM4E | |
| SCHEMBL25741974 | 0.72 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL24509702 | 0.71 | CTSA (0.31) | CTSAACHE | |
| SCHEMBL23732961 | 0.68 | TSHR (0.43) | KDM4E | |
| SCHEMBL25763341 | 0.68 | ALDH1A1 (0.59) | ALDH1A1KDM4E | |
| SCHEMBL28660598 | 0.67 | CTSA (0.43) | CTSAACHEALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL28669001 | 0.67 | ALDH1A1 (0.48) | CTSAACHEALDH1A1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833221-B2 | Oligomeric compounds for reducing DMPK expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230159922-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20220186222-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833221-B2 | Oligomeric compounds for reducing DMPK expression | DMPK, HNRNPK, MTPN | CTSA 1324/4885ACHE 4061/4885ALDH1A1 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.